227 related articles for article (PubMed ID: 15500415)
1. A benefit-risk assessment of class III antiarrhythmic agents.
Elming H; Brendorp B; Pehrson S; Pedersen OD; Køber L; Torp-Petersen C
Expert Opin Drug Saf; 2004 Nov; 3(6):559-77. PubMed ID: 15500415
[TBL] [Abstract][Full Text] [Related]
2. New advances in class III antiarrhythmic drug therapy.
Sager PT
Curr Opin Cardiol; 2000 Jan; 15(1):41-53. PubMed ID: 10666660
[TBL] [Abstract][Full Text] [Related]
3. Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues.
Wolbrette DL
Am J Cardiol; 2003 Mar; 91(6A):39D-44D. PubMed ID: 12670641
[TBL] [Abstract][Full Text] [Related]
4. Newer antiarrhythmic drugs.
Gupta AK; Maheshwari A; Thakur RK; Lokhandwala YY
Indian Heart J; 2001; 53(3):354-60. PubMed ID: 11516042
[No Abstract] [Full Text] [Related]
5. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes.
Shah SA; Kluger J; White CM
Pharmacotherapy; 2007 Sep; 27(9):1297-305. PubMed ID: 17723083
[TBL] [Abstract][Full Text] [Related]
6. New advances in class III antiarrhythmic drug therapy.
Sager PT
Curr Opin Cardiol; 1999 Jan; 14(1):15-23. PubMed ID: 9932203
[TBL] [Abstract][Full Text] [Related]
7. A review of class III antiarrhythmic agents for atrial fibrillation: maintenance of normal sinus rhythm.
Tsikouris JP; Cox CD
Pharmacotherapy; 2001 Dec; 21(12):1514-29. PubMed ID: 11765303
[TBL] [Abstract][Full Text] [Related]
8. Clinical differences between the newer antiarrhythmic agents.
Camm AJ
Europace; 2000 Jul; 1 Suppl C():C16-22. PubMed ID: 11220520
[TBL] [Abstract][Full Text] [Related]
9. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
[TBL] [Abstract][Full Text] [Related]
10. Class III antiarrhythmic drugs.
Singh BN; Ahmed R
Curr Opin Cardiol; 1994 Jan; 9(1):12-22. PubMed ID: 8199363
[TBL] [Abstract][Full Text] [Related]
11. [New anti-arrhythmia agents].
Honerjäger P; Schmidt G
Z Kardiol; 1992; 81 Suppl 4():133-7. PubMed ID: 1363260
[TBL] [Abstract][Full Text] [Related]
12. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
Bollmann A; Husser D; Cannom DS
Am J Cardiovasc Drugs; 2005; 5(6):371-8. PubMed ID: 16259525
[TBL] [Abstract][Full Text] [Related]
13. New antiarrhythmic drugs for the treatment of atrial fibrillation.
Castro A; Bianconi L; Santini M
Pacing Clin Electrophysiol; 2002 Feb; 25(2):249-59. PubMed ID: 11916001
[No Abstract] [Full Text] [Related]
14. Adjuvant antiarrhythmic therapy in patients with implantable cardioverter defibrillators.
Bunch TJ; Anderson JL
Am J Cardiovasc Drugs; 2014 Apr; 14(2):89-100. PubMed ID: 24288157
[TBL] [Abstract][Full Text] [Related]
15. Dofetilide: a new class III antiarrhythmic agent.
Roukoz H; Saliba W
Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):9-19. PubMed ID: 17187453
[TBL] [Abstract][Full Text] [Related]
16. Sotalol: An important new antiarrhythmic.
Anderson JL; Prystowsky EN
Am Heart J; 1999 Mar; 137(3):388-409. PubMed ID: 10047618
[TBL] [Abstract][Full Text] [Related]
17. Advantages and pitfalls of combining device-based and pharmacologic therapies for the treatment of ventricular arrhythmias: observations from a tertiary referral center.
Rajawat YS; Patel VV; Gerstenfeld EP; Nayak H; Marchlinski FE
Pacing Clin Electrophysiol; 2004 Dec; 27(12):1670-81. PubMed ID: 15613132
[No Abstract] [Full Text] [Related]
18. Pure class III agents for prevention of sudden cardiac death.
Pratt CM
J Cardiovasc Electrophysiol; 2003 Sep; 14(9 Suppl):S82-6. PubMed ID: 12950526
[TBL] [Abstract][Full Text] [Related]
19. Oral class III antiarrhythmics: what is new?
Khan MH
Curr Opin Cardiol; 2004 Jan; 19(1):47-51. PubMed ID: 14688634
[TBL] [Abstract][Full Text] [Related]
20. Current antiarrhythmic drugs: an overview of mechanisms of action and potential clinical utility.
Singh BN
J Cardiovasc Electrophysiol; 1999 Feb; 10(2):283-301. PubMed ID: 10090235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
